CRSP insider trading
NasdaqGM HealthcareCRISPR Therapeutics AG — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Company website: www.crisprtx.com
CRSP insider activity at a glance
FilingIQ has scored 1,068 insider transactions for CRSP since Oct 18, 2016. The most recent filing in our index is dated Mar 23, 2026.
Across the full history, 30 open-market purchases
and 511 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CRSP insider trades is 59.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CRSP Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading CRSP
Frequently asked
- How many insider trades does FilingIQ track for CRSP?
- FilingIQ tracks 1,068 Form 4 insider transactions for CRSP (CRISPR Therapeutics AG), covering filings from Oct 18, 2016 onwards. 45 of those were filed in the last 90 days.
- Are CRSP insiders net buyers or net sellers?
- Across the full Form 4 history for CRSP, 30 transactions (3%) were open-market purchases and 511 (48%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CRSP insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CRSP in?
- CRISPR Therapeutics AG (CRSP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.18B.
Methodology & sources
Every CRSP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.